tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Hold Rating on Merus’s Petosemtamab: Awaiting More Data for Colorectal Cancer Efficacy
PremiumRatingsHold Rating on Merus’s Petosemtamab: Awaiting More Data for Colorectal Cancer Efficacy
12d ago
Merus announces initial interim data from phase 2 trial of petosemtamab
Premium
The Fly
Merus announces initial interim data from phase 2 trial of petosemtamab
12d ago
Cautious Optimism: Hold Rating on Merus Amid Anticipation of Phase II Data Presentation and Genmab Acquisition
Premium
Ratings
Cautious Optimism: Hold Rating on Merus Amid Anticipation of Phase II Data Presentation and Genmab Acquisition
13d ago
Hold Rating on Genmab’s Acquisition of Merus Reflects Fair Valuation and Limited Upside Potential
PremiumRatingsHold Rating on Genmab’s Acquisition of Merus Reflects Fair Valuation and Limited Upside Potential
26d ago
Merus downgraded to Neutral from Buy at UBS
Premium
The Fly
Merus downgraded to Neutral from Buy at UBS
26d ago
Merus downgraded to Market Perform from Outperform at BMO Capital
Premium
The Fly
Merus downgraded to Market Perform from Outperform at BMO Capital
26d ago
Hold Rating Given to Merus Amid Genmab Acquisition Reflecting Full Stock Valuation and Strategic Asset Integration
PremiumRatingsHold Rating Given to Merus Amid Genmab Acquisition Reflecting Full Stock Valuation and Strategic Asset Integration
27d ago
Merus downgraded to Neutral from Buy at H.C. Wainwright
Premium
The Fly
Merus downgraded to Neutral from Buy at H.C. Wainwright
27d ago
Genmab price target raised to $34 from $32 at Leerink
Premium
The Fly
Genmab price target raised to $34 from $32 at Leerink
27d ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100